Top Injectable Manufacturer in Libya – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 3 days ago
- 10 min read
Last Updated: August 23, 2026
TL;DR: Medicines in Libya are regulated from inside the Ministry of Health rather than by a standalone agency: WHO EMRO identifies the Pharmacy Administration and its Registration Department as the country's drug regulatory authority, alongside the Food and Drug Control Centre (مركز الرقابة على الأغذية والأدوية) as the control and inspection body. Registration before marketing has been a legal requirement since Health Law No. 106 of 1973, but the African Union's own AMRH country assessment describes the registration process as inactive, hindered by a lack of independence, minimal infrastructure and a shortage of trained personnel — and the regulator publishes no dossier guideline, fee schedule or statutory timeline. Libya is not a PIC/S participating authority, applicant or pre-applicant, is not a party to the Hague Apostille Convention, and is not a party to the New York Convention on arbitral awards, so Indian CPP and GMP certificates need full consular legalisation and contracts need payment security rather than an arbitration clause. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling on ISO Class 5 aseptic lines, exporting to 30+ countries, and supplying CTD/ACTD-structured dossiers with ICH Q1A(R2) stability data.
Key Takeaways
Libya's regulator publishes almost nothing — so verify, never assume. WHO EMRO places the drug regulatory function in the Registration Department of the Ministry of Health's Pharmacy Administration, with the Food and Drug Control Centre as the control body, and registration has been legally required since Health Law No. 106 of 1973. But no dossier format, fee schedule, validity period or decision timeline is published anywhere, and the FDCC's own supplier and manufacturer service pages are empty. Any injectable manufacturer in Libya quoting a firm registration timeline is guessing.
The 4-billion-dinar tender restart contracts directly with manufacturers. On 4 June 2024 the Government of National Unity allocated LYD 4 billion to resume the national public medicines tender, suspended since 2009. Of the resulting awards, 122 contracts were signed directly with manufacturers — 78 of them for specialised medicines — financed mainly by the Central Bank of Libya, with more than 225 companies participating. The buying architecture explicitly contemplates manufacturer-level contracting.
There is effectively no domestic sterile injectable industry. The state flagship plant at Rabta has been non-productive for roughly fifteen years, and July 2025 talks with the Italian firm Pharmacom about reactivating it remain at the discussion stage. The one identified Libyan parenteral producer makes large-volume fluids only — normal saline and dextrose. No Libyan producer of ampoules, small-volume parenterals, lyophilised injectables or oncology injectables was identified, so import dependence in those categories is structural rather than cyclical.
Documentation and foreign exchange, not quality, are the real friction. Libya is not an Apostille party, so every Indian certificate goes through the full consular chain — and the Indian Embassy in Tripoli has been closed since April 2019, with Libya covered from Tunis. On the money side, the Central Bank devalued twice in nine months, to LYD 5.5677/USD in April 2025 and about LYD 6.3759/USD in January 2026, while the parallel market passed LYD 10.50/USD in February 2026.
Introduction: Why an Injectable Manufacturer in Libya Must Prove Quality on Evidence
Libya had a population of roughly 7.38 million in 2024 on World Bank figures, current health expenditure of USD 284.03 per person in 2022 at 4.74% of GDP, and an economy in which hydrocarbons supplied 65% of GDP, 93% of exports and 72% of government revenue in 2024. That is a country with money. What it does not have is a dependable delivery system: WHO's HeRAMS assessment in December 2024 found 8% of health facilities non-functioning and 84% only partially functional. The shortage is documented rather than asserted — a 2022 assessment by WHO and the Primary Health Care Institute covering 116 primary health-care facilities found acute shortages of antibiotics, insulin and blood-pressure medicines. Those are exactly the categories a sterile injectable supplier serves.
The complication is institutional rather than clinical. Since 2011 Libya has had rival executives — the Government of National Unity in Tripoli and the Government of National Stability in the east — and in August and September 2024 a contested Central Bank leadership was resolved only through UNSMIL-hosted talks. For a foreign supplier the practical consequence is unglamorous but decisive: customs and health administrations differ east and west, and a consignment cleared under one set of arrangements does not automatically clear under the other. Registration itself has been legally required since Health Law No. 106 of 1973, yet the African Union's AMRH country assessment states in its own words that medicine registration in Libya is inactive, held back by a lack of independence, minimal infrastructure and too few trained personnel. An honest supplier says so.
What Sets a World-Class Injectable Manufacturer in Libya Apart
Libya belongs to no regulatory club, and that shapes everything. It is not a PIC/S participating authority, not an applicant and not even a pre-applicant — while regional peers move the other way, with Saudi Arabia's SFDA acceding in July 2023 and Jordan's JFDA in January 2026. It is not a party to the Hague Apostille Convention, verified directly against the HCCH status table. It is a WTO observer and applicant, with a Working Party established on 27 July 2004, rather than a member. There is therefore no mutual-recognition shortcut and no reliance pathway a supplier can lean on. WHO-GMP status has to be demonstrated on evidence, not ticked off against a treaty. Practically, every Indian CPP, GMP certificate and corporate document travels the full consular chain — notary, state and MEA attestation, then Libyan mission legalisation — and with India's Tripoli embassy closed since April 2019 and Libya covered from Tunis, six to ten weeks of document lead time is realistic.
The demand side is where the case becomes concrete. GLOBOCAN 2024 estimates 8,070 new cancer cases and 4,717 cancer deaths a year in Libya, with a five-year prevalence of 19,366; lung cancer leads in men at 846 cases (20.1%) and breast cancer in women at 913 (23.7%), with a further 436 bladder cancers in men. Non-communicable diseases accounted for 79% of all deaths in 2019, the probability of premature NCD death between 30 and 70 was 19.8% in 2021, hypertension ran at 42.7% among adults aged 30 to 79 in 2019, and diabetes prevalence was 15.8% in 2024. Tuberculosis incidence was 63 per 100,000 in 2024, with 2,421 new cases notified in 2023 — a 47% jump on the year before. Layer on a heavy trauma and displacement load: 936,134 migrants recorded by IOM in early 2026, more than 240,000 Sudanese arrivals since April 2023, and landmine casualties across 436 million square metres of contaminated ground. That is an anaesthesia, analgesia, antibiotic, oncology and emergency-care profile.
Quality Systems Behind Every Batch We Ship to Libya
Everything leaves the Gujarat site through an ISO Class 5 aseptic core, with Grade A filling under Grade B background, routine media fills to qualify the aseptic process, and continuous viable and non-viable environmental monitoring. Each batch is released against sterility testing by the pharmacopoeial method, bacterial endotoxin testing by LAL, Karl Fischer determination of residual moisture on lyophilised presentations, HPLC and GC for assay, related substances and residual solvents, sub-visible and visible particulate matter, and container closure integrity. Analysis is written to USP, BP, IP or EP monographs according to the buyer's reference standard, and every batch ships with its certificate of analysis against retained samples held at the site.
Stability is generated under ICH Q1A(R2) on long-term and accelerated protocols at conditions appropriate to Libyan storage and transit, with ICH Q1B photostability where the molecule requires it. The documentation package is built to be filed rather than merely supplied: a Site Master File, validated master and executed batch records, DMF and CEP references where the API source supports them, and dossiers structured to CTD and ACTD. That completeness matters more in Libya than in most markets, precisely because the authority publishes no guideline and no deficiency procedure. A file that has to be corrected after submission has nowhere published to go, so it should be complete the first time.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Libya for Global Buyers
The single most actionable development for a manufacturer is the tender restart. On 4 June 2024 the Health Minister announced that LYD 4 billion had been allocated to resume the national public medicines tender, which had been suspended since 2009. What followed matters more than the headline number: 122 contracts were signed directly with manufacturers, 78 of them for specialised medicines, financed mainly by the Central Bank of Libya and processed in seven instalments, with more than 225 companies taking part in the deficiencies round. In other words, the procurement architecture explicitly contemplates contracting at manufacturer level rather than only through distributors. For a WHO-GMP certified producer able to document its own quality system end to end, that is a direct route into public supply rather than a theoretical one.
The second is the supply gap itself. The state flagship at Rabta, some 90 km south-west of Tripoli and run by the State Company for the Manufacture of Medicines and Medical Supplies, has been out of production for roughly fifteen years; discussions with the Italian firm Pharmacom in July 2025 about restarting it for raw-material production are the latest in a series going back to at least 2021, none of which has yet completed. The one Libyan parenteral producer identified, based in Tripoli, describes a range limited to large-volume fluids — normal saline and dextrose solutions. No Libyan manufacturer of ampoules, small-volume parenterals, lyophilised injectables or oncology injectables was identified at all. The humanitarian channel tells the same story from the other side: the ICRC delivered 60 tonnes of medical supplies to more than 30 facilities in 2024, explicitly including anaesthesia agents, injection materials, sterilisation items and sutures.
The risks deserve naming plainly, because a supplier who hides them is not a useful partner. Foreign exchange shapes every deal: the Central Bank devalued 13.3% effective 6 April 2025 to LYD 5.5677 per US dollar, then a further 14.7% effective 18 January 2026 to roughly LYD 6.3759, while the parallel market passed LYD 10.50 in February 2026 — a spread of around 65%. All imports must now be paid through official banking channels, and in March 2026 the Customs Authority introduced specialised security paper for official letters specifically to counter letter-of-credit forgery. Libya is not a party to the New York Convention, so a foreign arbitral award has no treaty route into Libyan courts: structure around payment security rather than dispute resolution. Transparency International scored Libya 13 out of 100 and ranked it 173rd of 180 in its 2024 index, and the World Bank's 2023 Logistics Performance Index put Libya at 1.9, the lowest of 139 economies. One point is worth stating because buyers routinely assume the opposite: Libya is not under a trade embargo. It is on neither the FATF grey nor black list, and the US Libya sanctions programme is targeted and list-based rather than comprehensive. Screen the counterparty, not the country.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer that can supply Libya?
Yes. Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, producing more than 100 injectable presentations — ampoules, vials, lyophilised powders for reconstitution and small-volume parenteral solutions — on ISO Class 5 aseptic fill-finish lines and exporting to more than 30 countries. For Libya the company supplies the documentation an importer needs to build a file: CTD- and ACTD-structured dossiers, ICH Q1A(R2) long-term and accelerated stability data, DMF and CEP references where the API source supports them, a Site Master File, executed batch records and certificates of analysis written to USP, BP, IP or EP monographs.
What does medicine registration in Libya actually involve?
The honest answer is that less is publicly established than most suppliers imply. Registration before marketing has been legally required since Health Law No. 106 of 1973, and WHO EMRO places the function in the Registration Department of the Ministry of Health's Pharmacy Administration, with the Food and Drug Control Centre acting as the control and inspection body. Beyond that, no dossier format, fee schedule, registration validity period or statutory decision timeline is published by the authority, and the African Union's AMRH assessment describes the registration process as inactive. We will not quote a timeline we cannot source. We prepare a complete CTD/ACTD file and support the importer in confirming current procedure with the authority directly.
Do Indian certificates need an apostille for use in Libya?
No — an apostille is not available for Libya, which is a different thing from not being needed. Libya does not appear in the Hague Apostille Convention status table, so Indian public documents cannot be apostilled for use there and instead require the full consular legalisation chain: notarisation, state and Ministry of External Affairs attestation, then legalisation by a Libyan diplomatic mission. Because the Indian Embassy in Tripoli has been closed since April 2019 and Libya is covered from Tunis, this step is the one most likely to slow a first shipment. Allow six to ten weeks and start it before, not after, commercial terms are agreed.
Can Libyan hospitals and importers buy directly from the manufacturer?
Yes, and the current procurement architecture explicitly allows for it. When the Government of National Unity restarted the national medicines tender in June 2024 with an allocation of LYD 4 billion, 122 of the resulting contracts were signed directly with manufacturers, 78 of them for specialised medicines, with more than 225 companies participating. Private importers and distributors remain the other principal route. One practical caution: because customs and health administrations operate separately in the west and the east, confirm at the outset which administration will clear the consignment, since arrangements made with one do not automatically carry over to the other.
Which injectables does Farbe Firma supply against Libyan demand?
The range maps onto Libya's documented burden. For oncology, against roughly 8,070 new cancer cases a year estimated by GLOBOCAN 2024, cytotoxic injectables and supportive-care products such as anti-emetics and corticosteroids. For the trauma, surgical and emergency load implied by a large displaced population and continuing explosive-remnant casualties, anaesthetic and analgesic injectables. Antibiotic injectables address the shortage WHO and the Primary Health Care Institute documented across 116 primary health-care facilities in 2022. Cardiovascular and diabetes-related injectables speak to hypertension at 42.7% and diabetes at 15.8%. Presentations cover ampoules, vials, lyophilised powders and small-volume parenterals.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments